Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0598934 (tumor growth)
 58,965 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Experimental and clinical studies were performed on aclarubicin in the treatment of solid tumors. In experimental cancer chemotherapy using human tumor xenografts transplanted to nude mice, aclarubicin showed a moderate antitumor effect (retardation of tumor growth) and nearly the same spectrum of activity in vivo as Adriamycin (doxorubicin). In in vitro sensitivity tests using 3H-thymidine uptake inhibition of a single cell suspension prepared from xenografts, aclarubicin showed a stronger inhibition than that of Adriamycin, mitomycin C and cyclophosphamide. In phase II clinical studies in patients with solid tumors, 3 intravenous dose schedules [schedule A: 20 mg (equal to 14 mg/m2) daily every other week, schedule B: 40 to 60 mg (28 to 42 mg/m2) twice a week, and schedule C: 60 to 100 mg (42 to 70 mg/m2) once a week] were investigated. Aclarubicin produced a 15 to 20% response rate for carcinomas of the stomach, lung, breast and ovary by schedules A and B. Dose-schedule limiting factors were digestive and hematologic toxicity.
 ...
PMID:Experimental and clinical studies on aclarubicin in the treatment of solid tumors. 659 63

In an attempt to improve the combined effects of hyperthermia and anti-cancer drugs, an intratumorous (i.t.) injection of the drugs was performed and its effect compared with that obtained by intraperitoneal (i.p.) injection. Using Lewis lung carcinoma growing in the legs of BDF1 mice, weakly toxic drug derivatives, Aclarubicin (ACR), a new platinum complex (DWA2114R), or Peplomycin (PEP) were injected either into the center of the tumors, or intraperitoneally, before or after usual hyperthemia in a 43.5-43.7 degrees C water bath for 45 min. The effects on tumor growth delay and the number of lung metastases were assessed, and the enhancement ratios (ERs) due to the combination were calculated. Tumor growth inhibition by i.t. injection was enhanced additively with ACR (ER; 1.2) and synergistically with DWA2114R (ER; 3.49) and PEP (ER; 2.4) plus hyperthermia. Hyperthermia after i.t. injections of DWA2114R (ER; 3.4) was more effective than either i.t. or i.p. injections after hyperthermia (ER; 2.4). Lung metastases were also inhibited significantly by the combination of hyperthermia and drugs, except when emulsified PEP was injected three times. It was concluded that the i.t. injection of DWA2114R was of value when used in combination with hyperthermia.
 ...
PMID:Synergistic effects of hyperthermia and intratumorous injection of anti-cancer drugs. 770 27